ERG protein expression as a biomarker of prostate cancer

Biomarkers in Medicine

Volumn 7, Issue 6, 2013, Pages 851-865

  Falzarano, Sara Moscovita ^a   Magi Galluzzi, Cristina ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ERG immunohistochemistry; genomic rearrangements; prostate cancer; TMPRSS2 ERG

Indexed keywords

TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS;

CANCER CLASSIFICATION; CANCER GRADING; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CARCINOGENESIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; ONCOGENE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PTEN GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TMPRSS2 ERG GENE;

ANTIBODIES, MONOCLONAL; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASTIC CELLS, CIRCULATING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889602820     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.105     Document Type: Review

References (90)

1. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005). (Pubitemid 41528150)
2. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am. J. Surg. Pathol. 31(6), 882-888 (2007). (Pubitemid 47165141)
3. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-Associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66(17), 8337-8341 (2006). (Pubitemid 44449140)
4. Petrovics G, Liu A, Shaheduzzaman S et al. Frequent overexpression of ETS-related gene 1 (ERG1) in prostate cancer transcriptome. Oncogene 24(23), 3847-3852 (2005). (Pubitemid 40826884)
5. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20(5), 538-544 (2007). (Pubitemid 46631996)
6. Braun M, Scheble VJ, Menon R et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 58(7), 1028-1036 (2011).
7. Falzarano SM, Navas M, Simmerman K et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod. Pathol. 23(11), 1499-1506 (2010).
8. Williamson SR, Zhang S, Yao JL et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod. Pathol. 24(8), 1120-1127 (2011).
9. Lotan TL, Gupta NS, Wang W et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24(6), 820-828 (2011).
10. Han B, Mehra R, Suleman K et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod. Pathol. 22(9), 1176-1185 (2009).
11. Gopalan A, Leversha MA, Dudas ME et al. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: Incidence and correlation with ERG immunohistochemistry. Histopathology 63(2), 279-286 (2013).
12. Falzarano SM, Zhou M, Carver P et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 459(4), 441-447 (2011).
13. Clark J, Merson S, Jhavar S et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26(18), 2667-2673 (2007). (Pubitemid 46632014)
14. Mosquera JM, Mehra R, Regan MM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 15(14), 4706-4711 (2009).
15. Furusato B, Gao CL, Ravindranath L et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod. Pathol. 21(2), 67-75 (2008). (Pubitemid 351172158)
16. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 23(8), 1061-1067 (2010).
17. Han B, Mehra R, Lonigro RJ et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 22(8), 1083-1093 (2009).
18. Mosquera JM, Perner S, Genega EM et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 14(11), 3380-3385 (2008).
19. Cerveira N, Ribeiro FR, Peixoto A et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8(10), 826-832 (2006). (Pubitemid 44564838)
20. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: Pathological features and ERG fusion status. J. Urol. 185(2), 489-494 (2011).
21. Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res. 67(17), 7991-7995 (2007). (Pubitemid 47395131)
22. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 70(4), 630-633 (2007). (Pubitemid 350030260)
23. Mehra R, Tomlins SA, Yu J et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68(10), 3584-3590 (2008).
24. Perner S, Svensson MA, Hossain RR et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 75(4), 762-767 (2010).
25. Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum. Pathol. 43(5), 644-649 (2012).
26. Tomlins SA, Laxman B, Varambally S et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10(2), 177-188 (2008). (Pubitemid 351240884)
27. Klezovitch O, Risk M, Coleman I et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci. USA 105(6), 2105-2110 (2008). (Pubitemid 351439472)
28. Carver BS, Tran J, Gopalan A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41(5), 619-624 (2009).
29. King JC, Xu J, Wongvipat J et al. Cooperativity of TMPRSS2-ERG with PI3 kinase pathway activation in prostate oncogenesis. Nat. Genet. 41(5), 524-526 (2009).
30. Braun M, Goltz D, Shaikhibrahim Z et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - A comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 15(2), 165-169 (2012).
31. Chaux A, Albadine R, Toubaji A et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol. 35(7), 1014-1020 (2011).
32. Furusato B, Tan SH, Young D et al. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13(3), 228-237 (2010).
33. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12(7), 590-598 (2010).
34. van Leenders GJ, Boormans JL, Vissers CJ et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: Implications for pathological practice. Mod. Pathol. 24(8), 1128-1138 (2011).
35. Teng LH, Wang C, Begin LR et al. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease. Urology 82(2), 394-399 (2013).
36. Minner S, Enodien M, Sirma H et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 17(18), 5878-5888 (2011).
37. Mohamed AA, Tan SH, Mikhalkevich N et al. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J. Cancer 1, 197-208 (2010).
38. Birdsey GM, Dryden NH, Amsellem V et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111(7), 3498-3506 (2008).
39. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch. Pathol. Lab. Med. 136(8), 935-946 (2012).
40. Gao X, Li LY, Zhou FJ et al. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin. Cancer Res. 18(15), 4163-4172 (2012).
41. He H, Magi-Galluzzi C, Li J et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am. J. Surg. Pathol. 35(4), 608-614 (2011).
42. He H, Osunkoya AO, Carver P et al. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): Lack of utility to stratify cancer risks associated with HGPIN. BJU Int. 110(11 Pt B), e751-e755 (2012).
43. Green WM, Hicks JL, De Marzo A, Illei PP, Epstein JI. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate. Hum. Pathol. 44(9), 1895-1901 (2013).
44. Shah RB, Tadros Y, Brummell B, Zhou M. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl- CoA-racemase markers. Hum. Pathol. 44(5), 786-794 (2013).
45. Yaskiv O, Zhang X, Simmerman K et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am. J. Surg. Pathol. 35(7), 1062-1068 (2011).
46. Clouston D, Bolton D. In situ and intraductal epithelial proliferations of prostate: Definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia. BJU Int. 109(Suppl. 3), 22-26 (2012).
47. Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J. Urol. 184(5), 1958-1962 (2010).
48. Shah RB, Zhou M. Atypical cribriform lesions of the prostate: Clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate. Adv. Anat. Pathol. 19(4), 270-278 (2012).
49. Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: Emphasis on radical prostatectomy findings. J. Urol. 184(4), 1328-1333 (2010).
50. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J. Urol. 175(Pt 1), 820-834 (2006). (Pubitemid 43199991)
51. Han B, Suleman K, Wang L et al. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am. J. Surg. Pathol. 34(4), 478-485 (2010).
52. Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 97(5), 678-685 (2007). (Pubitemid 47339893)
53. Lotan TL, Gurel B, Sutcliffe S et al. PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin. Cancer Res. 17(20), 6563-6573 (2011).
54. Lotan TL, Gumuskaya B, Rahimi H et al. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod. Pathol. 26(4), 587-603 (2013).
55. Liu H, Shi J, Wilkerson M, Yang XJ, Lin F. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues. Ann. Clin. Lab. Sci. 43(1), 3-9 (2013).
56. Miettinen M, Wang ZF, Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am. J. Surg. Pathol. 35(3), 432-441 (2011).
57. Yaskiv O, Rubin BP, He H, Falzarano S, Magi-Galluzzi C, Zhou M. ERG protein expression in human tumors detected with a rabbit monoclonal antibody. Am. J. Clin. Pathol. 138(6), 803-810 (2012).
58. Minner S, Luebke AM, Kluth M et al. High level of Ets-related gene expression has high specificity for prostate cancer: A tissue microarray study of 11 483 cancers. Histopathology 61(3), 445-453 (2012).
59. Guo CC, Dancer JY, Wang Y et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum. Pathol. 42(1), 11-17 (2011).
60. Scheble VJ, Braun M, Wilbertz T et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56(7), 937-943 (2010).
61. Schelling LA, Williamson SR, Zhang S et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum. Pathol. 44(10), 2227-2233 (2013).
62. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66(17), 8347-8351 (2006). (Pubitemid 44449142)
63. Rajput AB, Miller MA, De Luca A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60(11), 1238-1243 (2007). (Pubitemid 350084545)
64. Cheville JC, Karnes RJ, Therneau TM et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncol. 26(24), 3930-3936 (2008).
65. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6(1), 40-45 (2007). (Pubitemid 46294173)
66. Nam RK, Sugar L, Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 97(12), 1690-1695 (2007). (Pubitemid 350249347)
67. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin. Cancer Res. 14(11), 3395-3400 (2008).
68. Hermans KG, Boormans JL, Gasi D et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin. Cancer Res. 15(20), 6398-6403 (2009).
69. Gopalan A, Leversha MA, Satagopan JM et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 69(4), 1400-1406 (2009).
70. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3), 253-263 (2008).
71. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31), 4596-4599 (2007). (Pubitemid 47037039)
72. Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur. J. Cancer 48(4), 538-546 (2012).
73. Spencer ES, Johnston RB, Gordon RR et al. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate 73(9), 905-912 (2013).
74. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17(5), 1033-1036 (2007).
75. Pettersson A, Graff RE, Bauer SR et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-Analysis. Cancer Epidemiol. Biomarkers Prev. 21(9), 1497-1509 (2012).
76. Hoogland AM, Jenster G, van Weerden WM et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod. Pathol. 25(3), 471-479 (2012).
77. Szász AM, Majoros A, Rosen P et al. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. Int. Urol. Nephrol. 45(3), 727-733 (2013).
78. Hu Y, Dobi A, Sreenath T et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin. Cancer Res. 14(15), 4719-4725 (2008).
79. Yoshimoto M, Joshua AM, Cunha IW et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 21(12), 1451-1460 (2008).
80. Oikawa T. ETS transcription factors: Possible targets for cancer therapy. Cancer Sci. 95(8), 626-633 (2004). (Pubitemid 39255808)
81. Brenner JC, Ateeq B, Li Y et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5), 664-678 (2011). classification of prostate cancer according to ERG rearrangement status.
82. Chatterjee P, Choudhary GS, Sharma A et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE 8(4), e60408 (2013).
83. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 17(12), 3903-3912 (2011).
84. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69(7), 2912-2918 (2009).
85. Danila DC, Anand A, Sung CC et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 60(5), 897-904 (2011).
86. Rostad K, Hellwinkel OJ, Haukaas SA et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 117(8), 575-582 (2009).
87. Tomlins SA, Aubin SM, Siddiqui J et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3(94), 94ra72 (2011).
88. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13(17), 5103-5108 (2007). (Pubitemid 47502077)
89. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 73(3), 242-249 (2013).
90. Leyten GH, Hessels D, Jannink SA et al.: Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. doi:10.1016/j. eururo.2012.11.014 (2012) (Epub ahead of print).